Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Incomplete Resection Thymoma or Thymic Carcinoma
NCT02633514Phase 3Withdrawn
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), etoposide in thymoma, thymic carcinoma (TC), sponsored by Fudan University. Planned start Dec 2023; status: withdrawn.
02
Drugs
Cisplatin micelle injection (HA132)etoposide
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT02633514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633514.